文献速递糖尿病肥胖与代谢综合征

肠促胰素激素与2型糖尿病

Incretin hormones and type 2 diabetes.
PubMed 文献 · Diabetologia · 2023-07-11

肠促胰素激素(GIP和GLP-1)参与2型糖尿病病理生理,其衍生物在降糖、心肾结局和体重方面显示治疗成功。2型糖尿病中肠促胰素效应显著降低或缺失,与GIP刺激胰岛素分泌能力下降有关,而GLP-1的胰岛素促泌效能受损较轻。基于肠促胰素的药物(选择性GLP-1受体激动剂及GIP/GLP-1受体共激动剂如替尔泊肽)可改善血糖和体重。

要点

  • 2型糖尿病中肠促胰素效应显著降低或缺失,与GIP刺激胰岛素分泌能力下降有关。
  • GLP-1的胰岛素促泌效能受损较轻,外源性GLP-1可刺激胰岛素分泌、抑制胰高血糖素分泌并降低血糖。
  • 替尔泊肽(GIP/GLP-1受体共激动剂)降低HbA1c和体重的效果优于选择性GLP-1受体激动剂(如司美格鲁肽)。

核心结论

  • 肠促胰素激素及其衍生物在2型糖尿病治疗中显示成功,未来同时刺激肠促胰素激素及其他受体的药物可能进一步提高控制血糖和诱导体重减轻的能力。

研究设计与样本

  • 综述性文章,围绕肠促胰素激素(GIP和GLP-1)在2型糖尿病病理生理及治疗中的作用进行阐述。

主要发现

  • 2型糖尿病中肠促胰素效应(口服葡萄糖后胰岛素分泌反应大于等血糖静脉葡萄糖)显著降低或缺失。
  • 肠促胰素效应降低可能与GIP刺激胰岛素分泌能力下降有关,原因包括β细胞功能整体受损或GIP信号通路特异性缺陷。
  • GLP-1的胰岛素促泌效能受损较轻,外源性GLP-1可刺激胰岛素分泌、抑制胰高血糖素分泌并降低空腹和餐后血糖。
  • 替尔泊肽(GIP/GLP-1受体共激动剂)降低2型糖尿病患者HbA1c和体重的效果优于选择性GLP-1受体激动剂(如司美格鲁肽)。

临床怎么用

  • 基于肠促胰素的降糖药物包括选择性GLP-1受体激动剂及较新的共激动剂(如刺激GIP和GLP-1受体)。
  • 替尔泊肽作为GIP/GLP-1受体共激动剂,在2型糖尿病患者中降低HbA1c和体重方面比选择性GLP-1受体激动剂(如司美格鲁肽)更有效。

局限性

  • GIP受体激动在长期暴露于替尔泊肽后如何促进更好血糖控制和体重减轻的机制是活跃研究领域。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Incretin hormones (glucose-dependent insulinotropic polypeptide [GIP] and glucagon-like peptide-1 [GLP-1]) play a role in the pathophysiology of type 2 diabetes. Along with their derivatives they have shown therapeutic success in type 2 diabetes, with the potential for further improvements in glycaemic, cardiorenal and body weight-related outcomes. In type 2 diabetes, the incretin effect (greater insulin secretory response after oral glucose than with 'isoglycaemic' i.v. glucose, i.e. with an identical glycaemic stimulus) is markedly reduced or absent. This appears to be because of a reduced ability of GIP to stimulate insulin secretion, related either to an overall impairment of beta cell function or to specific defects in the GIP signalling pathway. It is likely that a reduced incretin effect impacts on postprandial glycaemic excursions and, thus, may play a role in the deterioration of glycaemic control. In contrast, the insulinotropic potency of GLP-1 appears to be much less impaired, such that exogenous GLP-1 can stimulate insulin secretion, suppress glucagon secretion and reduce plasma glucose concentrations in the fasting and postprandial states. This has led to the development of incretin-based glucose-lowering medications (selective GLP-1 receptor agonists or, more recently, co-agonists, e.g. that stimulate GIP and GLP-1 receptors). Tirzepatide (a GIP/GLP-1 receptor co-agonist), for example, reduces HbA1c and body weight in individuals with type 2 diabetes more effectively than selective GLP-1 receptor agonists (e.g. semaglutide). The mechanisms by which GIP receptor agonism may contribute to better glycaemic control and weight loss after long-term exposure to tirzepatide are a matter of active research and may change the pessimistic view that developed after the disappointing lack of insulinotropic activity in people with type 2 diabetes when exposed to GIP in short-term experiments. Future medications that stimulate incretin hormone and other receptors simultaneously may have the potential to further increase the ability to control plasma glucose concentrations and induce weight loss.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Nauck MA, Müller TD. Incretin hormones and type 2 diabetes. Diabetologia. 2023. PMID: 37430117. doi:10.1007/s00125-023-05956-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。